Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of TNX-102 SL 2.8 mg from Two Manufacturers
NCT03168022Phase 1Completed
- Sponsor
- Tonix Pharmaceuticals
- Start
- Dec 2015
- Primary completion
- Jan 2016
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Tonmya in fibromyalgia (FM) and post-traumatic stress disorder (PTSD) (2 arms), sponsored by Tonix Pharmaceuticals. Primary endpoints: Mean Plasma Concentration Area Under the Curve and Treatment-Emergent Adverse Events at 1 month. Started Dec 2015; status: completed.
02
Drugs
Tonmya
03
Conditions
fibromyalgia (FM)post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT03168022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03168022.